Skip to main content
. 2013 Dec 9;6(2):403–408. doi: 10.4161/mabs.27443

graphic file with name mabs-6-403-g4.jpg

Figure 4. Trastuzumab plus saracatinib combinatorial treatment inhibits the in vivo growth of both NCI-N87 and NCI-N87R gastric cancer cell lines. Tumor volume of NCI-N87 or NCI-N87R xenografts after treatment with control IgG (10 mg/kg), trastuzumab (10 mg/kg), saracatinib (25 mg/kg), or trastuzumab (10 mg/kg) plus saracatinib (25 mg/kg). Data are shown as means ± SEM ***P < 0.0001, Mann-Whitney test.